Indian Pharma’s Biologics Push: Game-Changer in Cancer Care

Direct Listing on Foreign Exchanges Unleashing Potential
Share

Explore the impact of biologics in cancer treatment and their relevance for Indian pharmaceutical companies.

The Indian pharmaceutical industry has emerged as a global powerhouse, crucial in providing affordable and high-quality medicines to people worldwide. With a rich history rooted in traditional healing practices, India has transformed into a pharmaceutical hub. The industry contributes significantly to the global healthcare landscape.

The roots of the Indian pharmaceutical sector can be traced back to ancient times when traditional healing systems like Ayurveda and Unani were developed. The country’s commitment to research, development, and innovation has laid the foundation for growth and global recognition. Today, India is the largest provider of generic drugs globally and has earned a significant reputation for its affordable vaccines and generic medicines.

The Indian pharmaceutical sector continues to invest in new research and innovation, especially in addressing complex diseases like cancer globally.

What’s Happening?

Indian drug companies are investing in biologics, especially for the effective and safe treatment of diseases like cancer, autoimmune disorders, and chronic conditions. According to Dr Sanjay Chaturvedi, CEO of Aurobindo Pharma, as quoted in Business Today, “Biologic drugs are in global demand for the treatment of complex diseases such as cancer, autoimmune disorders, and chronic conditions. Indian companies aim to enter this expanding market and provide advanced treatment options”.

What Are Biologics?

In simple terms, biologics are medicines derived from living organisms or other natural sources. The process of making biologics is not as straightforward. Modern biotechnology allows scientists to take components from humans, animals, or microorganisms and use them to create biologics.

Several types of medicines and vaccines fall under the category of biologics and are currently available mainly in injection form. While some biologics, such as vaccines and insulin, are readily available in your local pharmacy, others may only be obtained from specific speciality pharmacies. These drugs tend to be more complex, making biologics more expensive than other medicines. Biologics are commonly used to treat health conditions such as cancer, autoimmune disorders, and chronic conditions.

Biologics in Cancer Treatment: How Can It Be Effective?

Biologics present a diversified model for conditions lacking effective solutions in traditional therapies and alternative treatments. Biologics, especially those targeting specific molecules and pathways, have shown increased effectiveness in treating cancer-related molecules and pathways.

Biologics aim to enhance the body’s strategic response against cancer. This includes advanced treatments like CAR T-cell therapy and checkpoint inhibitors. Utilising the body’s immune system to combat cancer, these treatments may be more expensive than traditional chemotherapy but offer fewer side effects and increased effectiveness for various cancer types.

What’s Next?

According to Invest India, the market size of the Indian pharmaceutical industry is expected to reach 65 billion US dollars by 2024 and potentially 130 billion US dollars by 2030.

As per a recent report by EY FICCI, there is a growing consensus among patients in favour of providing new innovative therapies. Therefore, the Indian pharmaceutical market is expected to reach 130 billion US dollars by the end of 2030.

That’s it for today. We hope you’ve found this article informative. Remember to spread the word among your friends. Until we meet again, stay curious!

*The article is for information purposes only. This is not an investment advice.

*Disclaimer: https://tejimandi.com/disclaimer

Teji Mandi Multiplier Portfolio of high quality companies that blends shorter term tactical bets with long term winners Subscription Fee
CAGR
Min. Investment
Teji Mandi Multiplier Portfolio

Teji Mandi Multiplier

Concentrated portfolio of fundamentally strong small & midcap stocks that are likely to show potential growth.

2Y CAGR

Min. Investment

Subscription Fee

Teji Mandi Flagship A basket of 15-20 long-term and tactical stocks that we regularly rebalance to adjust to the market conditions. Subscription Fee
CAGR
Min. Investment
Teji mandi Flagship portfolio

Teji Mandi Flagship

A Multi-Cap portfolio of 15-20 stocks that consists of tactical bets and long-term winners that generate index-beating returns.

3Y CAGR

Min. Investment

Subscription Fee

Recommended Articles

"Register Your Interest"